{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:49:08Z","timestamp":1792100948191,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Synthetic lethality is emerging as an important cancer therapeutic paradigm, while the comprehensive selective treatment opportunities for various tumors have not yet been explored. We develop the Synthetic Lethality Knowledge Graph (SLKG), presenting the tumor therapy landscape of synthetic lethality (SL) and synthetic dosage lethality (SDL). SLKG integrates the large-scale entity of different tumors, drugs and drug targets by exploring a comprehensive set of SL and SDL pairs. The overall therapy landscape is prioritized to identify the best repurposable drug candidates and drug combinations with literature supports, in vitro pharmacologic evidence or clinical trial records. Finally, cladribine, an FDA-approved multiple sclerosis treatment drug, is selected and identified as a repurposable drug for treating melanoma with CDKN2A mutation by in vitro validation, serving as a demonstrating SLKG utility example for novel tumor therapy discovery. Collectively, SLKG forms the computational basis to uncover cancer-specific susceptibilities and therapy strategies based on the principle of synthetic lethality.<\/jats:p>","DOI":"10.1038\/s41467-021-21544-2","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T11:03:35Z","timestamp":1614164615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["The tumor therapy landscape of synthetic lethality"],"prefix":"10.1038","volume":"12","author":[{"given":"Biyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2417-6663","authenticated-orcid":false,"given":"Chi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1342-8941","authenticated-orcid":false,"given":"Shuyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-1221","authenticated-orcid":false,"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"21544_CR1","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1158\/1078-0432.CCR-15-0088","volume":"21","author":"KS Tewari","year":"2015","unstructured":"Tewari, K. S., Eskander, R. N. & Monk, B. J. Development of olaparib for BRCA-deficient recurrent epithelial ovarian cancer. Clin. Cancer Res. 21, 3829\u20133835 (2015).","journal-title":"Clin. Cancer Res."},{"key":"21544_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/cancers5030739","volume":"5","author":"BV Sajesh","year":"2013","unstructured":"Sajesh, B. V., Guppy, B. J. & McManus, K. J. Synthetic genetic targeting of genome instability in cancer. Cancers 5, 739\u2013761 (2013).","journal-title":"Cancers"},{"key":"21544_CR3","doi-asserted-by":"publisher","unstructured":"Dwane, L. et al. Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets. Nucleic Acids Res. 1\u20138 (2020). https:\/\/doi.org\/10.1093\/nar\/gkaa882","DOI":"10.1093\/nar\/gkaa882"},{"key":"21544_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cell.2017.07.005","volume":"170","author":"ER McDonald","year":"2017","unstructured":"McDonald, E. R. et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170, 577\u2013592.e10 (2017).","journal-title":"Cell"},{"key":"21544_CR5","doi-asserted-by":"publisher","first-page":"D1011","DOI":"10.1093\/nar\/gkv1108","volume":"44","author":"J Guo","year":"2016","unstructured":"Guo, J., Liu, H. & Zheng, J. SynLethDB: Synthetic lethality database toward discovery of selective and sensitive anticancer drug targets. Nucleic Acids Res. 44, D1011\u2013D1017 (2016).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576.e16 (2017).","journal-title":"Cell"},{"key":"21544_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ccr.2014.08.008","volume":"26","author":"CJ Ryan","year":"2014","unstructured":"Ryan, C. J., Lord, C. J. & Ashworth, A. DAISY: Picking synthetic lethals from cancer genomes. Cancer Cell 26, 306\u2013308 (2014).","journal-title":"Cancer Cell"},{"key":"21544_CR8","doi-asserted-by":"publisher","first-page":"D833","DOI":"10.1093\/nar\/gkw943","volume":"45","author":"J Pi\u00f1ero","year":"2017","unstructured":"Pi\u00f1ero, J. et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 45, D833\u2013D839 (2017).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR9","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 45, D777\u2013D783 (2017).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jgg.2016.12.004","volume":"44","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Sun, J. & Zhao, M. ONGene: a literature-based database for human oncogenes. J. Genet. Genomics 44, 119\u2013121 (2017).","journal-title":"J. Genet. Genomics"},{"key":"21544_CR11","doi-asserted-by":"publisher","first-page":"D1023","DOI":"10.1093\/nar\/gkv1268","volume":"44","author":"M Zhao","year":"2016","unstructured":"Zhao, M., Kim, P., Mitra, R., Zhao, J. & Zhao, Z. TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res. 44, D1023\u2013D1031 (2016).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR12","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/nar\/gkr797","volume":"40","author":"F Zhu","year":"2012","unstructured":"Zhu, F. et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40, 1128\u20131136 (2012).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/nar\/gkt1068","volume":"42","author":"V Law","year":"2014","unstructured":"Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, 1091\u20131097 (2014).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR14","doi-asserted-by":"publisher","first-page":"D1036","DOI":"10.1093\/nar\/gkv1165","volume":"44","author":"AH Wagner","year":"2016","unstructured":"Wagner, A. H. et al. DGIdb 2.0: Mining clinically relevant drug-gene interactions. Nucleic Acids Res. 44, D1036\u2013D1044 (2016).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nbt.2151","volume":"30","author":"P Sanseau","year":"2012","unstructured":"Sanseau, P. et al. Use of genome-wide association studies for drug repositioning. Nat. Biotechnol. 30, 317\u2013320 (2012).","journal-title":"Nat. Biotechnol."},{"key":"21544_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/nbt.2758","volume":"31","author":"ZY Wang","year":"2013","unstructured":"Wang, Z. Y. & Zhang, H. Y. Rational drug repositioning by medical genetics. Nat. Biotechnol. 31, 1080\u20131082 (2013).","journal-title":"Nat. Biotechnol."},{"key":"21544_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-018-0546-1","volume":"10","author":"E Pi\u00f1eiro-Y\u00e1\u00f1ez","year":"2018","unstructured":"Pi\u00f1eiro-Y\u00e1\u00f1ez, E. et al. PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. Genome Med. 10, 1\u201311 (2018).","journal-title":"Genome Med."},{"key":"21544_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/bioinformatics\/btr709","volume":"28","author":"R Kolde","year":"2012","unstructured":"Kolde, R., Laur, S., Adler, P. & Vilo, J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 28, 573\u2013580 (2012).","journal-title":"Bioinformatics."},{"key":"21544_CR19","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2147\/TCRM.S149248","volume":"14","author":"DC Pearre","year":"2018","unstructured":"Pearre, D. C. & Tewari, K. S. Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. Ther. Clin. Risk Manag. 14, 2189\u20132201 (2018).","journal-title":"Ther. Clin. Risk Manag."},{"key":"21544_CR20","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1002\/cncr.31307","volume":"124","author":"A Turk","year":"2018","unstructured":"Turk, A. & Wisinski, K. B. PARP inhibition in BRCA-mutant breast. Cancer Cancer 124, 2498 (2018).","journal-title":"Cancer Cancer"},{"key":"21544_CR21","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi, A. D. et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 156, 2242\u20132253.e4 (2019).","journal-title":"Gastroenterology"},{"key":"21544_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10637-012-9891-x","volume":"31","author":"N Walsh","year":"2013","unstructured":"Walsh, N. et al. EGFR and HER2 inhibition in pancreatic cancer. Investig. N. Drugs 31, 558\u2013566 (2013).","journal-title":"Investig. N. Drugs"},{"key":"21544_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151\u20131161 (2013).","journal-title":"Cell"},{"key":"21544_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, 955\u2013961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/bib\/bbx172","volume":"20","author":"R Wang","year":"2018","unstructured":"Wang, R. et al. Link synthetic lethality to drug sensitivity of cancer cells. Brief. Bioinform. 20, 1295\u20131307 (2018).","journal-title":"Brief. Bioinform."},{"key":"21544_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291\u2013304.e6 (2018).","journal-title":"Cell"},{"key":"21544_CR27","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1016\/j.celrep.2018.05.034","volume":"23","author":"K Sullivan-Reed","year":"2018","unstructured":"Sullivan-Reed, K. et al. Simultaneous targeting of PARP1 and RAD52 triggers dual synthetic lethality in BRCA-deficient tumor cells. Cell Rep. 23, 3127\u20133136 (2018).","journal-title":"Cell Rep."},{"key":"21544_CR28","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.2147\/DDDT.S82035","volume":"9","author":"H Sui","year":"2015","unstructured":"Sui, H., Shi, C., Yan, Z. & Li, H. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Drug Des. Devel. Ther. 9, 3183\u20133190 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"21544_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/nar\/gkh061","volume":"32","author":"O Bodenreider","year":"2004","unstructured":"Bodenreider, O. The unified medical language system (UMLS): integrating biomedical terminology. Nucleic Acids Res. 32, 267\u2013270 (2004).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR30","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45(W1)","author":"Z Tang","year":"2017","unstructured":"Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res., 45(W1), W98\u2013W102.(2017).","journal-title":"Nucleic Acids Res."},{"key":"21544_CR31","doi-asserted-by":"crossref","unstructured":"Bulat, Z. et al. DrugComb: an integrative cancer drug combination data portal. Nucleic Acids Res, 47(W1), W43\u2013W51 (2019).","DOI":"10.1093\/nar\/gkz337"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21544-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21544-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21544-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:45:37Z","timestamp":1669977937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21544-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21544"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21544-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1275"}}